Myo-Inositol Effects on Pregnancy Outcomes and Fetal Growth
International Journal of Medical Sciences and Pharma Research · 15.03.2026 · 12 (1) · 11-13
DOI: 10.22270/ijmspr.v12i1.170 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Medical Sciences and Pharma Research, online erschienen am 15.03.2026. Verfasst von Mukesh Kumar und 3 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Myo-inositol (MI), a naturally occurring carbocyclic sugar and second messenger in insulin signaling, has emerged as a supplement of interest in pregnancy due to its potential metabolic and reproductive effects. This review summarizes current evidence on MI supplementation during pregnancy, with special emphasis on maternal outcomes (e.g., gestational diabetes mellitus [GDM], hypertensive disorders), neonatal outcomes like preterm birth, birthweight, and implications for fetal growth. Keywords: Myo-Inositol, GDM, Fetal growth, Diabetes
Zitieren
APA
Kumar, M., Singh, H., Iqbali, T., & Shah, R. (2026). Myo-Inositol Effects on Pregnancy Outcomes and Fetal Growth. International Journal of Medical Sciences and Pharma Research, 12(1), 11-13. https://doi.org/10.22270/ijmspr.v12i1.170
Vancouver
Kumar M, Singh H, Iqbali T, Shah R. Myo-Inositol Effects on Pregnancy Outcomes and Fetal Growth. International Journal of Medical Sciences and Pharma Research. 2026;12(1):11-13. doi:10.22270/ijmspr.v12i1.170
BibTeX
@article{Kumar2026,
author = {Kumar, Mukesh and Singh, Harpreet and Iqbali, Tauhid and Shah, Ravi},
title = {Myo-Inositol Effects on Pregnancy Outcomes and Fetal Growth},
journal = {International Journal of Medical Sciences and Pharma Research},
year = {2026},
volume = {12},
number = {1},
pages = {11--13},
doi = {10.22270/ijmspr.v12i1.170}
}
EUVIMED